Predicting survival of cancer patients by chromosomal copy number heterogeneity

Tom Van Den Bosch; Erik van Dijk; Louis Vermeulen; Daniël M Miedema

doi:10.1080/23723556.2021.1949956

Predicting survival of cancer patients by chromosomal copy number heterogeneity

Mol Cell Oncol. 2021 Aug 3;8(4):1949956. doi: 10.1080/23723556.2021.1949956. eCollection 2021.

Authors

Tom Van Den Bosch^{1

2}, Erik van Dijk³, Louis Vermeulen^{1

2}, Daniël M Miedema^{1

2}

Affiliations

¹ LEXOR, Center for Experimental and Molecular Medicine, Cancer Center Amsterdam and Amsterdam Gastroenterology & Metabolism, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
² Oncode Institute, Amsterdam, The Netherlands.
³ Department of Pathology, Cancer Center Amsterdam, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Abstract

We recently introduced a method to derive intra-tumor heterogeneity (ITH) from a single copy number measurement. This method stratifies patients for survival and could potentially help to identify low and high-risk patients with clinical relevance.

Keywords: Biomarker; chromosomal instability; intra-tumor heterogeneity; pan-cancer.

Grants and funding

This work was supported by Amsterdam UMC and Oncode; by a talent development grant of the AG&M institute of Amsterdam UMC and a Young Investigator Grant of KWF [12215] to D.M.M.; L.V. is a New York Stem Cell Foundation - Robertson Investigator.